Tesamorelin + Ipamorelin

What Is the Tesamorelin + Ipamorelin Combination?

Tesamorelin is a synthetic analog of the full-length growth hormone-releasing hormone (GHRH), modified to resist rapid breakdown in the body. It's FDA-approved under the brand name Egrifta specifically for reducing visceral abdominal fat in people with HIV-associated lipodystrophy, backed by large Phase 3 clinical trials.

Ipamorelin is a structurally unrelated peptide that activates a different receptor entirely, the ghrelin receptor, rather than the GHRH receptor tesamorelin targets. It's best known in the research literature for its selectivity, stimulating growth hormone release without meaningfully raising cortisol or prolactin the way some older compounds in its class do. Because the two peptides work through separate receptors that both ultimately drive growth hormone release, they're frequently studied and used together.

What This Combination Is Being Researched For

• Visceral Fat Reduction

  Tesamorelin's approved research base centers on reducing visceral abdominal fat, with large Phase 3 trials showing significant reductions in people with HIV-associated lipodystrophy.^[1]

• Selective Growth Hormone Release

  Ipamorelin's research base centers on its ability to stimulate growth hormone release while leaving other pituitary hormones largely unaffected, a selectivity profile established in its original characterization.^[2]

• Combined Pathway Research

  Because the two peptides activate separate receptors that both feed into growth hormone release, researchers combining them are generally interested in whether the two signals together produce a more complete response than either alone.

How the Combination Works

• Tesamorelin and the GHRH Pathway

  Research points to tesamorelin binding to GHRH receptors in the pituitary gland, triggering growth hormone release and a subsequent rise in IGF-1, with effects on fat metabolism directed preferentially at visceral fat tissue.^[1]

• Ipamorelin and the Ghrelin Receptor

  Research points to Ipamorelin activating the ghrelin receptor, a separate pathway from GHRH, producing a single pulse of growth hormone release without significantly affecting cortisol, prolactin, or ACTH.^[2]

• Why the Two Are Paired

  Since tesamorelin and Ipamorelin activate different receptors that both lead to growth hormone release, researchers studying this combination are generally looking at whether the two separate signals together produce a stronger or more complete response than triggering just one pathway.

Reconstitution and Handling

Tesamorelin is available as an FDA-approved pharmaceutical product, but research-grade vials of both tesamorelin and ipamorelin sold as lyophilized powder are common and require reconstitution with bacteriostatic water before use. Water should be added slowly rather than injected directly into the powder, and the vial should be swirled, not shaken.

Since the amount of water used affects the concentration of the final solution, researchers often use a dosage calculator to work this out for each peptide separately before mixing. Once reconstituted, both solutions are kept refrigerated to help preserve stability.

Key Takeaways

Tesamorelin and Ipamorelin are paired because they activate two separate receptor pathways that both feed into growth hormone release, GHRH for tesamorelin and the ghrelin receptor for Ipamorelin. Tesamorelin carries real FDA approval and large clinical trial data behind its specific indication, while Ipamorelin remains a well-characterized research compound without that regulatory backing. Most of what's published studies each peptide individually rather than in combination.

Frequently Asked Questions

Sources and Research

1. Falutz J, Allas S, Blot K, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007;357(23):2359-2370.
2. Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561.